Literature DB >> 8918918

Paracrine activation of the HIV-1 LTR promoter by the viral Tat protein is mechanistically similar to trans-activation within a cell.

K Verhoef1, A Klein, B Berkhout.   

Abstract

The HIV-1 Tat protein activates transcription of the viral LTR promoter through interaction with the nuclear transcription machinery of the host cell. Tat can also activate the LTR promoter in a paracrine or inter-cellular manner by a yet unknown mechanism. One possibility is that Tat protein itself is secreted by cells and taken up by other cells. According to this mechanism, inter-cellular transcriptional activation by Tat should be very similar to intra-cellular trans-activation in Tat-producing cells. A large number of cytokine genes was recently reported to be Tat-responsive, raising the possibility that such cytokines and the corresponding cellular transduction pathways are involved in inter-cellular Tat action. The transcriptional events in such an indirect route are likely to differ from intra-cellular Tat action. To discriminate between a direct or indirect mechanism of inter-cellular Tat action, we compared the activity of a set of Tat mutants and different promoter constructs in inter-cellular and intra-cellular transcriptional activation. Identical results were obtained in both assays, suggesting that Tat protein itself is exported by one and transported into the nucleus of another cell. The demonstration that Tat antibodies specifically inhibit the inter-cellular route is also consistent with cell-to-cell transport of the Tat protein. Furthermore, we found that the second Tat coding exon, including the RGD motif that has been proposed to interact with an integrin receptor, is not required for cellular uptake of the Tat protein.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8918918     DOI: 10.1006/viro.1996.0606

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  7 in total

1.  Optimal Tat-mediated activation of the HIV-1 LTR promoter requires a full-length TAR RNA hairpin.

Authors:  K Verhoef; M Tijms; B Berkhout
Journal:  Nucleic Acids Res       Date:  1997-02-01       Impact factor: 16.971

2.  Identification of new and unusual rev and nef transcripts expressed by an HIV type 1 primary isolate.

Authors:  Yolanda Vega; Elena Delgado; Cristina Carrera; Paloma Nebreda; Aurora Fernández-García; María Teresa Cuevas; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  AIDS Res Hum Retroviruses       Date:  2013-05-08       Impact factor: 2.205

Review 3.  Genetic variation and HIV-associated neurologic disease.

Authors:  Satinder Dahiya; Bryan P Irish; Michael R Nonnemacher; Brian Wigdahl
Journal:  Adv Virus Res       Date:  2013       Impact factor: 9.937

4.  Paracrine in vivo inhibitory effects of hepatitis B virus X protein (HBx) on liver cell proliferation: an alternative mechanism of HBx-related pathogenesis.

Authors:  J Guilherme Tralhao; Jean Roudier; Serban Morosan; Carlo Giannini; Hong Tu; Cyril Goulenok; Françoise Carnot; Flora Zavala; Virginie Joulin; Dina Kremsdorf; Christian Bréchot
Journal:  Proc Natl Acad Sci U S A       Date:  2002-05-14       Impact factor: 11.205

5.  A second-site mutation that restores replication of a Tat-defective human immunodeficiency virus.

Authors:  K Verhoef; B Berkhout
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  Identification of new splice sites used for generation of rev transcripts in human immunodeficiency virus type 1 subtype C primary isolates.

Authors:  Elena Delgado; Cristina Carrera; Paloma Nebreda; Aurora Fernández-García; Milagros Pinilla; Valentina García; Lucía Pérez-Álvarez; Michael M Thomson
Journal:  PLoS One       Date:  2012-02-17       Impact factor: 3.240

7.  The HIV-1 virion-associated protein vpr is a coactivator of the human glucocorticoid receptor.

Authors:  T Kino; A Gragerov; J B Kopp; R H Stauber; G N Pavlakis; G P Chrousos
Journal:  J Exp Med       Date:  1999-01-04       Impact factor: 14.307

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.